{
  "id": "nclex_ngn_sa_011",
  "itemType": "standalone",
  "questionType": "priorityAction",
  "question": {
    "stem": "The nurse is caring for a 78-year-old client in the emergency department with a history of heart failure (HF) with reduced ejection fraction. The client is diagnosed with new-onset atrial fibrillation with a rapid ventricular response (RVR). The provider has entered an order for diltiazem IV push. The nurse is preparing to administer the medication. Which action should the nurse take first?",
    "tabs": [
      {
        "id": "tab1",
        "label": "Nurses' Note",
        "content": "**1400:** Client arrived via private vehicle. Reports 12 hours of worsening palpitations, shortness of breath, and lightheadedness. States, \"I felt too weak to come in sooner.\" Client is pale, diaphoretic, and anxious. A&O x4. Lung sounds with bibasilar crackles. 2+ pitting edema noted to bilateral lower extremities."
      },
      {
        "id": "tab2",
        "label": "Vital Signs",
        "content": "| Time | HR (bpm) | BP (mmHg) | RR (breaths/min) | SpO2 (%) |\n|---|---|---|---|---|\n| **1405** | 165 | 108/68 | 24 | 93% (RA) |\n| **1430** | 172 | 84/50 | 28 | 90% (RA) |"
      },
      {
        "id": "tab3",
        "label": "Diagnostic Results",
        "content": "**12-Lead ECG Interpretation (1410):**\nAtrial fibrillation, ventricular rate 168/min. No evidence of acute ischemia.\n\n**Laboratory Results (1425):**\n- Potassium: 3.4 mEq/L (3.5-5.0 mEq/L)\n- BUN: 32 mg/dL (10-20 mg/dL)\n- Creatinine: 1.9 mg/dL (0.6-1.2 mg/dL)\n- Serum Lactate: 4.1 mmol/L (0.5-2.2 mmol/L)\n- Troponin I: <0.04 ng/mL (<0.04 ng/mL)"
      },
      {
        "id": "tab4",
        "label": "MAR",
        "content": "| Medication | Dose | Route | Frequency | Time Due |\n|---|---|---|---|---|\n| Diltiazem | 20 mg | IV | STAT, one time | Now |"
      }
    ],
    "options": [
      {
        "id": "opt1",
        "label": "A",
        "content": "Administer the diltiazem 20 mg IV push as ordered."
      },
      {
        "id": "opt2",
        "label": "B",
        "content": "Apply oxygen via a non-rebreather mask at 15 L/min."
      },
      {
        "id": "opt3",
        "label": "C",
        "content": "Withhold the diltiazem and contact the provider immediately."
      },
      {
        "id": "opt4",
        "label": "D",
        "content": "Request an order for an IV fluid bolus of 0.9% sodium chloride."
      }
    ],
    "correctOptionId": "opt3"
  },
  "rationale": {
    "correct": "The client is exhibiting signs of cardiogenic shock, a life-threatening condition where the heart cannot pump enough blood to meet the body's needs. The key indicators are the significant drop in blood pressure (from 108/68 mmHg to 84/50 mmHg), persistent tachycardia (HR 172 bpm), tachypnea (RR 28 breaths/min), and desaturation (SpO2 90% on room air). The elevated serum lactate (4.1 mmol/L) indicates anaerobic metabolism due to tissue hypoperfusion, and the elevated BUN (32 mg/dL) and creatinine (1.9 mg/dL) suggest acute kidney injury secondary to decreased renal perfusion. Diltiazem is a calcium channel blocker that works by slowing the heart rate and decreasing blood pressure through vasodilation and negative inotropic effects (reduced contractility). In a client already experiencing hypotension and impaired cardiac output, administering diltiazem would further compromise hemodynamics, potentially leading to cardiovascular collapse. Therefore, the nurse's priority is to withhold the diltiazem (a 'Safety Stop' action) and immediately notify the provider to advocate for a change in the plan of care. The provider may consider alternative treatments such as synchronized cardioversion to restore normal sinus rhythm or vasopressors to support blood pressure.",
    "incorrect": "The incorrect options either fail to recognize the emergent change in condition, represent a direct safety threat, or are not the most critical priority action in this rapidly deteriorating situation.",
    "answerBreakdown": [
      {
        "label": "A",
        "content": "Administer the diltiazem 20 mg IV push as ordered.",
        "isCorrect": false,
        "justification": "This action is extremely dangerous and contraindicated. Diltiazem's mechanism of action (vasodilation and negative inotropy) will exacerbate the client's hypotension and further reduce cardiac output, potentially leading to cardiovascular collapse. This is a 'Do Not Proceed' action due to the high risk of patient harm."
      },
      {
        "label": "B",
        "content": "Apply oxygen via a non-rebreather mask at 15 L/min.",
        "isCorrect": false,
        "justification": "While the client is hypoxic and requires oxygen supplementation, this is a secondary priority. The hypoxia is a consequence of the underlying cardiogenic shock and poor perfusion. Addressing the shock state by preventing further hemodynamic compromise is the immediate priority. Oxygen administration can be delegated to another member of the healthcare team."
      },
      {
        "label": "C",
        "content": "Withhold the diltiazem and contact the provider immediately.",
        "isCorrect": true,
        "justification": "This is the correct priority action. It demonstrates critical clinical judgment by recognizing the client's deteriorating condition and the contraindication of diltiazem in the setting of hypotension and cardiogenic shock. Withholding a potentially harmful medication and escalating care to the provider for alternative treatment options (e.g., cardioversion, vasopressors) is the essential life-saving step."
      },
      {
        "label": "D",
        "content": "Request an order for an IV fluid bolus of 0.9% sodium chloride.",
        "isCorrect": false,
        "justification": "This action is inappropriate and potentially harmful. The client has a history of heart failure and clinical signs of fluid overload (bibasilar crackles, pitting edema). The shock is cardiogenic (pump failure), not hypovolemic. Administering a fluid bolus would likely worsen pulmonary edema and respiratory distress, further compromising respiratory function without addressing the underlying cause of the shock."
      }
    ]
  },
  "pedagogy": {
    "bloomLevel": "Evaluate",
    "cjmmStep": "Take Action",
    "nclexCategory": "Physiological Adaptation",
    "nclexSubcategory": "Hemodynamics",
    "difficulty": "Level 4 (Discriminating)",
    "topicTags": [
      "Atrial Fibrillation",
      "Cardiogenic Shock",
      "Medication Safety",
      "Contraindication",
      "Clinical Judgment",
      "Hemodynamic Instability"
    ]
  },
  "sbar": {
    "situation": "A 78-year-old client with a history of heart failure (HF) with reduced ejection fraction presented to the emergency department with new-onset atrial fibrillation with a rapid ventricular response (RVR).",
    "background": "At 1400, the client reported 12 hours of worsening palpitations, shortness of breath, and lightheadedness. Initial vital signs at 1405 showed a heart rate of 165 bpm, blood pressure of 108/68 mmHg, respiratory rate of 24 breaths/min, and SpO2 of 93% on room air. An ECG confirmed atrial fibrillation with a ventricular rate of 168/min. Laboratory results at 1425 showed a potassium level of 3.4 mEq/L, BUN of 32 mg/dL, creatinine of 1.9 mg/dL, serum lactate of 4.1 mmol/L, and troponin I <0.04 ng/mL.",
    "assessment": "The client's condition has deteriorated. At 1430, vital signs are: HR 172 bpm, BP 84/50 mmHg, RR 28 breaths/min, and SpO2 90% on room air. The client is pale, diaphoretic, and anxious with bibasilar crackles and 2+ pitting edema in the lower extremities. Elevated lactate and creatinine suggest the client is developing cardiogenic shock. The provider has ordered diltiazem 20 mg IV push STAT.",
    "recommendation": "I recommend withholding the diltiazem due to the client's current hypotensive state and signs of cardiogenic shock. Diltiazem will further decrease blood pressure and cardiac output. I recommend the provider re-evaluate the treatment plan, considering synchronized cardioversion or vasopressor support. Please advise."
  },
  "clinicalPearl": "Diltiazem is contraindicated in patients with hypotension or cardiogenic shock due to its negative inotropic and vasodilatory effects. Always assess the patient's hemodynamic status, including blood pressure, heart rate, and signs of end-organ perfusion (e.g., urine output, mental status), before administering this medication. Worsening hypotension, elevated lactate levels, and signs of acute kidney injury (AKI) are critical indicators of cardiogenic shock and warrant immediate intervention.",
  "sentinelStatus": "healed_v2026_v8"
}